Head-To-Head Contrast: RadNet (RDNT) versus Its Rivals

RadNet (NASDAQ: RDNT) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare RadNet to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

55.8% of RadNet shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 9.4% of RadNet shares are held by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares RadNet and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RadNet 0.01% 26.01% 1.98%
RadNet Competitors -118.65% -181.74% -42.76%

Volatility & Risk

RadNet has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, RadNet’s peers have a beta of 1.23, meaning that their average stock price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for RadNet and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RadNet 0 0 1 2 3.67
RadNet Competitors 107 450 529 17 2.41

RadNet currently has a consensus target price of $14.67, suggesting a potential upside of 1.85%. As a group, “Medical laboratories” companies have a potential upside of 20.36%. Given RadNet’s peers higher possible upside, analysts plainly believe RadNet has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares RadNet and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
RadNet $922.19 million $50,000.00 49.66
RadNet Competitors $1.13 billion $76.65 million 202.61

RadNet’s peers have higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

RadNet peers beat RadNet on 7 of the 13 factors compared.

RadNet Company Profile

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply